Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds.
Level 5 - mechanism / opinion, no new human data
In vitro cell-based molecular phenotyping study without human participants
PubMed 37960259 · doi:10.3390/nu15214607
What was done
Human cell-based molecular phenotyping assays across 12 cell systems were used to compare the bioactivities and dose responses of pentadecanoic acid (C15:0) with three candidate longevity compounds: acarbose, metformin, and rapamycin.
What was found
C15:0 demonstrated 36 dose-dependent activities across 10 of 12 cell systems, compared to 32 activities across all 12 systems for rapamycin. At optimal concentrations (17 µM for C15:0 and 9 µM for rapamycin), C15:0 and rapamycin shared 24 activities across 10 cell systems, including lowering inflammatory markers (MCP-1, TNFα, IL-10, and IL-17A/F) alongside antifibrotic and anticancer phenotypic activities. Quantitative comparative data for acarbose and metformin were not reported in the abstract.
Why it matters
This study demonstrates that the odd-chain fatty acid C15:0 shares broad in vitro cellular signaling profiles with rapamycin, providing preclinical mechanistic rationale for further evaluation in metabolic and aging-related research.
Limits
This was an in vitro cell-culture assay study with no in vivo animal or human clinical testing. Cell-culture phenotypes cannot establish bioavailability, pharmacokinetics, safety, or clinical efficacy for human healthspan or longevity. Numerical comparative results for acarbose and metformin were omitted from the abstract.
Cited by
- partial C15 (pentadecanoic acid) strengthens cells to support healthy aging.